PharmaShots Weekly Snapshots (April 11-15, 2022)
Published: Apr 15, 2022 | Tags: BMS, Nektar, Bempegaldesleukin, Opdivo, Renal Cell Carcinoma, Bladder Cancer
SonoScape Receives the US FDA’s Approval for its Endoscopy System
Published: Apr 15, 2022 | Tags: SonoScape, US, FDA, Approval, Endoscopy System, HD-550
Published: Apr 15, 2022 | Tags: Boehringer Ingelheim, Autigen, Collaborate, Discover, Develop, Novel Treatments, Hearing Loss
Valneva Received MHRA’s Conditional Marketing Authorization for its Inactivated COVID-19 Vaccine
Published: Apr 15, 2022 | Tags: Valneva, MHRA, Conditional Marketing Authorization, Inactivated COVID-19 Vaccine
Published: Apr 15, 2022 | Tags: Pfizer, BioNTech, Approval, Booster Dose, COVID-19 Vaccine, Children
Amneal Receives the US FDA’s Approval for Alymsys (biosimilar, bevacizumab)
Published: Apr 15, 2022 | Tags: Amneal, US, FDA, Almysys, biosimilar, Bevacizumab
Merck’s V116 Receives the US FDA’s Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease & Pneumococcal Pneumonia
Published: Apr 14, 2022 | Tags: Merck, V116, US, FDA, Breakthrough Therapy Designation, Invasive Pneumococcal Disease, Pneumococcal Pneumonia
CG Oncology Presents Interim Results of CG0070 + Keytruda (pembrolizumab) in P-II (CORE1) Study for NMIBC Unresponsive to Bacillus Calmette-Guerin at AACR 2022
Published: Apr 14, 2022 | Tags: CG Oncology, CG0070, Keytruda, pembrolizumab, P-II, CORE1 Study, NMIBC, Bacillus Calmette-Guerin, AACR, 2022
Sanofi Publishes Results of Rilzabrutinib in P-I/II Study for the Treatment of Immune Thrombocytopenia in NEJM
Published: Apr 14, 2022 | Tags: Sanofi, Rilzabrutinib, P-I/II Study, Immune Thrombocytopenia, NEJM
Halozyme Entered into a Definitive Agreement to Acquire Antares for ~$960M
Published: Apr 14, 2022 | Tags: Halozyme, Acquire, Antares, ~$960M
Published: Apr 14, 2022 | Tags: AbbVie, Genmab, Epcoritamab, P-I/II, EPCORE NHL-1 Trial, Large B-cell Lymphoma
Published: Apr 14, 2022 | Tags: Astellas, Padcev, enfortumab vedotin, EC, Approval, Urothelial Cancer
Published: Apr 13, 2022 | Tags: LENZ, Ji Xing, LNZ100, LNZ101, Presbyopia, Greater China
Published: Apr 13, 2022 | Tags: Apexigen, Sotigalimab, Pembrolizumab, P-II Trial, Metastatic Melanoma, AACR, 2022
Published: Apr 13, 2022 | Tags: AbbVie, Navitoclax, Ruxolitinib, P-II, REFINE Trial, Myelofibrosis, AACR 2022
GSK to Acquire Sierra Oncology for ~$1.9B
Published: Apr 13, 2022 | Tags: GSK, Acquire, Sierra Oncology, ~$1.9B
Published: Apr 13, 2022 | Tags: Boehringer Ingelheim, Eli Lilly, Health Canada, Marketing Authorization, Jardiance, empagliflozin, HFpEF
Published: Apr 13, 2022 | Tags: Actinium, Immedica, Iomab-B, 131I apamistamab, EU, Middle East, North Africa
Takeda Reports Results of Takhzyro (lanadelumab) in P-III (SHP643-301/ SPRING) Study for the Treatment of Hereditary Angioedema
Published: Apr 12, 2022 | Tags: Takeda, Takhzyro, lanadelumab, P-III, SHP643-301, SPRING Study, Hereditary Angioedema
Published: Apr 12, 2022 | Tags: Engitix, 2020, License Agreement, Takeda, Anti-Fibrotic Therapies, Inflammatory Bowel Disease
Published: Apr 12, 2022 | Tags: BMS, Opdivo, nivolumab, P-III, CheckMate-816 Trial, Resectable, Non-Small Cell Lung Cancer
Published: Apr 12, 2022 | Tags: Lilly, Lebrikizumab, P-III, ADhere Study, Atopic Dermatitis, RAD, 2022
Published: Apr 12, 2022 | Tags: BioNTech, Matinas BioPharma, Technology, mRNA-Based Vaccines
Ardelyx Amends 2017 Agreement with Kyowa Kirin for Tenapanor to Treat Hyperphosphatemia in Japan
Published: Apr 12, 2022 | Tags: Ardelyx, Amends, 2017, Agreement, Kyowa Kirin, Tenapanor, Hyperphosphatemia, Japan
Published: Apr 11, 2022 | Tags: Junshi, Coherus, Toripalimab, P-III, JUPITER-02 Study, Nasopharyngeal Carcinoma, AACR, 2022
BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III (ALPINE) Trial for the Treatment of Chronic Lymphocytic Leukemia
Published: Apr 11, 2022 | Tags: BeiGene, Brukinsa, zanubrutinib, P-III, ALPINE Trial, Chronic Lymphocytic Leukemia
Published: Apr 11, 2022 | Tags: Gannex, P-II, Clinical Trial, ASC42, Primary Biliary Cholangitis
Telix Entered into a Licence Agreement with Lilly to Develop and Commercialise Olaratumab for Cancer
Published: Apr 11, 2022 | Tags: Telix, Lilly, Olaratumab, Cancer
Amgen Presents Results of Lumakras (sotorasib) in P-I/II (CodeBreaK 100) Trial for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer at AACR 2022
Published: Apr 11, 2022 | Tags: Amgen, Lumakras, sotorasib, P-I/II, CodeBreaK 100 Trial, KRAS G12C-Mutated, Advanced, Non-Small Cell Lung Cancer, AACR 2022
Published: Apr 11, 2022 | Tags: Blueprint, BLU-945, P-I/II, SYMPHONY Trial, EGFR-Mutant, Non-Small Cell Lung Cancer
Related Post: PharmaShots Weekly Snapshots (April 04-08, 2022)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com